Statement of Principles concerning schizophrenia (Reasonable Hypothesis) (No. 27 of 2026)

Reasonable hypothesis. This is the evidentiary standard drawn from section 120A of the VEA. It does not require the decision-maker to be satisfied that the factor actually caused the disease, only that there is a “reasonable hypothesis” connecting the factor to the disease, supported by sound medical-scientific evidence. The RMA determines that such sound evidence exists for the factors listed. This is a low-threshold gateway: once a factor is found, the claim must be accepted unless there is evidence to the contrary that is so strong as to disprove the hypothesis beyond reasonable doubt , an extremely high bar in practice.

Schizophrenia definition. The SoP does not rely solely on ICD-10-AM coding. It requires the full DSM-5-TR diagnostic criteria (from the American Psychiatric Association, 2022 edition) to be met. That includes six criteria: (A) two or more symptoms (delusions, hallucinations, disorganised speech, grossly disorganised/catatonic behaviour, negative symptoms) present for at least one month; (B) marked functional decline; (C) continuous signs for at least six months; (D) exclusion of schizoaffective and mood disorders; (E) not due to substance or another medical condition; and (F) if autism or communication disorder history exists, prominent delusions or hallucinations are required. This definition is narrower than clinical practice in some settings, where the six-month criterion is often applied more loosely. The ICD-10-AM codes F20.0-F20.3, F20.5, F20.9 are only for coding reference; the disease meaning is strictly per DSM-5-TR.

Factors. The core of the instrument lies in section 9, which lists 17 factors that must exist to raise a hypothesis. Each factor has a temporal relationship to either “clinical onset” or “clinical worsening”. “Clinical onset” means the first appearance of symptoms meeting the diagnostic criteria. “Clinical worsening” is not defined in the instrument but is used in several factors (items 8-9, 11-17). Section 10(2) limits the clinical worsening factors to situations where schizophrenia was suffered or contracted before or during relevant service but did not arise out of it , that is, the worsening must be a material contribution to or aggravation of a pre-existing condition that was not service-related.

Category 1A and 1B stressors. These are definitions of severe traumatic events. 1A includes life-threatening event, serious physical attack or assault including rape or sexual molestation, and being threatened with a weapon, held captive, kidnapped, or tortured. 1B includes killing or maiming a person, witnessing a person being killed or critically injured, witnessing atrocities, and witnessing human remains or critically injured casualties (excluding closed body bags or open-casket viewing). The witness definition (Schedule 1) requires direct experience at the time of the incident, excluding exposure through broadcast or mass media.

Specified drug lists. List 1 (for alcohol or substance use disorder factor) covers amphetamines, cocaine, opioids. List 2 (for factor 18: taking a drug from that list within 30 days before clinical worsening) covers a broader set including aciclovir, bupropion, cannabis, hallucinogens, inhalants, mefloquine, phenelzine, varenicline, and many others. The lists are exhaustive and not illustrative.

Clinical worsening factors. Items 16-20 address clinical worsening rather than onset. They include having a clinically significant disorder of mental health (defined as one of sufficient severity to warrant ongoing management, without requiring actual management), taking a medication that redevelops or worsens symptoms, taking a List 2 drug, ceasing/changing antipsychotic therapy, and inability to obtain appropriate clinical management. The last factor (item 20) is particularly open-ended; it does not define what constitutes “appropriate” management or what level of inability is required, creating potential for interpretive disputes.

The SoP directly affects three groups: (1) current and former members of the Australian Defence Force and their dependants who are claiming compensation for schizophrenia under the VEA or MRCA; (2) the decision-making bodies , the Repatriation Commission, the Military Rehabilitation and Compensation Commission, and the Administrative Appeals Tribunal , which must apply the SoP to claims; and (3) medical assessors and psychiatrists who prepare reports for claimants, as they must understand the DSM-5-TR criteria and the specific factor definitions.

Claimants. A person with relevant service (operational, peacekeeping, hazardous, or British nuclear test defence service under the VEA; warlike or non-warlike service under the MRCA) who develops schizophrenia or whose schizophrenia is aggravated during service can rely on the SoP to establish a reasonable hypothesis. The instrument does not cover veterans who served only in peacetime non-operational service (which is covered by the Safety, Rehabilitation and Compensation Act 1988, not the VEA/MRCA unless special provisions apply). Nor does it cover civilians.

Decision-makers and the appeals system. The SoP removes some discretion by predetermining what constitutes a reasonable hypothesis. Decision-makers cannot accept a hypothesis based on factors not listed, unless the claimant can point to other medical-scientific evidence that meets the reasonable hypothesis standard and is not covered by the SoP , a rare occurrence given the RMA’s role as the authoritative body. In practice, the SoP functions as a checklist. That reduces the risk of inconsistent outcomes but also reduces flexibility for unusual cases.

Legal and medical professionals. The instrument increases the importance of precise diagnosis and documentation. A clinician who records “possible schizophrenia” or uses an older DSM edition may disqualify the claim if the diagnosis cannot be confirmed to DSM-5-TR standard. Similarly, the timing of events (e.g., infection with Toxoplasma gondii within five years before onset) requires careful history-taking. The lists of drugs mean that prescribing records and drug screening may become relevant.

The wider health system. While the instrument itself is limited to veteran compensation, the definitions may influence medico-legal standards in other jurisdictions, as the RMA’s SoPs are often cited in common law and workers’ compensation contexts. The emphasis on DSM-5-TR over ICD-10-AM coding is notable and may create confusion for psychiatrists used to coding with ICD. The instrument also imposes a compliance cost on the compensation system: processing claims with multiple complex factors requires medical record retrieval, specialist reports, and often external review.

The SoP does not create duties or rights directly; those arise from the VEA and MRCA. But the SoP defines the content of the duty to determine claims according to the reasonable hypothesis standard. The key duty on the Repatriation Commission and MRCC is to apply the SoP correctly. That means they must:

• Verify that the claimed condition meets the DSM-5-TR diagnosis of schizophrenia, not merely an ICD-10-AM code.
• Identify which, if any, of the 17 factors exist, and confirm they occurred within the specified time windows relative to clinical onset or worsening.
• Apply the dictionary definitions strictly, especially for “category 1A stressor” (which excludes events like witnessing a non-critical injury, or being threatened without a weapon) and “witness” (which excludes indirect exposure).
• Distinguish between clinical onset and clinical worsening factors, and apply section 10(2) for worsening cases (only where schizophrenia existed before or during service but did not arise from service).
• Ensure that factors that refer to another injury or disease (section 11) are cross-referenced to the relevant SoP for that condition. For example, factor 1 (childhood harm) involves serious physical, emotional, or sexual harm, which may itself be a psychological injury requiring its own SoP.
• Give the claimant the benefit of any reasonable doubt in applying the hypothesis standard, but only after the SoP’s conditions are met.

Rights of the claimant. The claimant has a right to have the claim assessed under the most recent SoP in force at the time of decision (though the instrument applies from commencement). The claimant can argue that a factor not listed still raises a reasonable hypothesis based on other medical-scientific evidence, but the RMA’s determination that only the listed factors meet the “sound medical-scientific evidence” test creates a strong presumption against such arguments. The claimant can also challenge the RMA’s findings in the AAT or Federal Court, but judicial review is limited to errors of law, not merits.

No duty to treat or manage. The SoP does not impose any duty on the Department of Veterans’ Affairs to provide specific treatment for schizophrenia. It is an entitlement instrument only. The “inability to obtain appropriate clinical management” factor (item 20) does not create a right to management; it only creates a pathway for a worsening claim if management was unavailable.

The duty on medical practitioners is de facto: they must provide reports that meet the SoP’s standards. An inaccurate or incomplete report can lead to claim rejection or appeal costs. There is no formal duty in the instrument, but the practical effect is that clinicians must be familiar with DSM-5-TR and the factor definitions.

This SoP does not contain penalty provisions. It is a standard-setting instrument, not a regulatory prohibition. Enforcement relates to the underlying Acts. The VEA has criminal penalties for making false statements in claims (sections 213-214 of the VEA, up to 12 months imprisonment) and for obtaining benefits by fraud. The MRCA has similar provisions. The SoP itself is not directly enforced; it is applied as binding policy by the Commission.

However, the instrument does have an indirect enforcement mechanism. If a decision-maker fails to apply the SoP correctly, the claimant can appeal. If the Commission repeatedly misapplies it, the matter can be taken to the AAT or Federal Court. The RMA has no enforcement role; its only function is to determine and revoke SoPs.

The compliance burden falls on claimants to provide evidence satisfying the SoP’s criteria. There is no penalty for a claimant who fails to meet the criteria; they simply lose the claim. But there is potential for perjury charges if they fabricate factors (e.g., claiming a category 1A stressor that did not occur). The risk of detection is low unless the Commission or Tribunal cross-examines the claimant.

The SoP’s strict definitions (e.g., witness excludes media coverage, category 1B excludes seeing a closed body bag) create opportunities for the Commission to reject claims on technical interpretation without penalty to the Commission. Conversely, if the Commission misinterprets a definition to the claimant’s detriment, the claimant’s remedy is an appeal, not a penalty against the Commission.

The instrument’s operation also creates a system of “gaming” incentives: claimants and their lawyers may emphasise factors that are easier to prove (e.g., childhood harm, which can be self-reported with minimal corroboration) over less accessible ones. The Commission’s enforcement is limited to verifying evidence; it cannot second-guess a credible self-report unless there is contradictory evidence. This asymmetry tends to favour the claimant in the reasonable hypothesis framework.

The SoP operates within the framework of the VEA and MRCA. Section 120A of the VEA and section 338 of the MRCA require the RMA to determine SoPs for injuries and diseases associated with service. The SoP overrides any common law or earlier policy on the reasonable hypothesis standard for schizophrenia. Section 11 of the instrument provides that if a factor refers to an injury or disease covered by another SoP, the factors of that other SoP apply. For example, factor 1 (childhood harm) might involve an adjustment disorder or PTSD; if that condition has its own SoP, the relevant factors from that SoP must also be satisfied to use factor 1. This creates a cascading system of SoPs.

The instrument repeals and replaces SoP No. 83 of 2016. A claim lodged before 23 March 2026 may still be determined under the old SoP if the claim was made before commencement, but after that date all new claims and reviewable decisions must use the new SoP. The definitions in the new SoP differ from the old: the new version adds SARS-CoV-2 infection, updates the DSM edition from DSM-5 to DSM-5-TR, and adds new drug lists. The temporal windows for some factors may have changed (though the 2016 text is not provided for comparison).

The SoP also interacts with the Therapeutic Goods Administration’s scheduling of drugs and with state and territory poisons acts, importing definitions of “inhalants” and “organic solvents” that are not identical across jurisdictions. The definitions in Schedule 1 are autonomous: “inhalants” means breathable chemicals that produce psychoactive vapours, including organic solvents, aerosols and anaesthetics. “Organic solvents” lists four subcategories. These are not tied to any external regulation, which means a substance could be an inhalant for SoP purposes even if not scheduled under drugs legislation.

The SoP’s reference to ICD-10-AM Tenth Edition (2017) is notable. ICD-10-AM has since been updated to Eleventh Edition, but the SoP deliberately fixes the reference to the 2017 version. This may create tension if clinicians use newer WHO ICD-11 codes, but for SoP purposes the schizophrenia definition is per DSM-5-TR anyway; the ICD codes are only for indexing.

The instrument does not interact with state workers’ compensation laws directly, but it may influence them indirectly because the RMA’s SoPs are often cited as authoritative in other jurisdictions. However, state tribunals are not bound by this SoP.

The instrument notes it is issued under subsection 196B(2) of the VEA. It commences on 23 March 2026 and repeals the Statement of Principles concerning schizophrenia No. 83 of 2016 (F2016L01682). The instrument does not provide a full legislative history, but the cited instrument was made under the same subsection of the VEA. No other prior SOPs are mentioned. The RMA may amend or revoke the instrument at any time if new medical-scientific evidence warrants changes. There is no statutory requirement for the RMA to review SoPs on a fixed cycle, but in practice the RMA does update them periodically as evidence evolves. The 2026 version appears to be a relatively minor update: adding COVID-19 infection and updating the DSM reference. It is reasonably current as of 2026, but note that DSM-5-TR was released in 2022; the 2016 SoP likely used DSM-5 (2013). Over time, further revisions may add more psychiatric conditions or expand the drug lists.

The instrument itself references no cases. However, the underlying reasonable hypothesis standard and the RMA’s SoPs have been extensively litigated in the Federal Court and High Court. Notable principles established in earlier decisions include: the RMA cannot rely on a single medical hypothesis without “sound medical-scientific evidence”; the factors must be more than theoretical possibilities; and the RMA must have regard to the whole of the medical evidence, not just selective studies. But because the user’s source text does not mention any specific litigation, we must not cite case names. The instrument’s definitions will likely be tested if a claimant argues that a factor (e.g., “inability to obtain appropriate clinical management”) is too vague or that the DSM-5-TR criteria are not the only valid diagnostic standard. The strict definitions of stressors may also be challenged. The instrument is not immune to constitutional challenge, but as a legislative instrument under a valid Act, it is presumptively valid.

1. DSM-5-TR exclusivity. The diagnosis must meet all six DSM-5-TR criteria, including the six-month duration and the requirement that schizoaffective and mood disorders be ruled out. Many clinicians diagnose schizophrenia based on ICD-10 guidelines which allow shorter duration or different exclusions. A claimant accepted for pension under a broader clinical diagnosis may be rejected if the SoP diagnosis is not satisfied. The ICD-10-AM codes are only for reference; the Commission will require evidence that the specific DSM criteria are met.

2. Temporal traps. Each factor has a strict time window. For example, viral meningitis before age 16 is only relevant if schizophrenia onset occurs within 15 years thereafter. Moderate to severe traumatic brain injury must occur within five years before onset. Concussion requires onset within six months. SARS-CoV-2 infection must be within one month before onset. These windows are arbitrary from an epidemiological perspective; a claimant with a plausible link outside the window will fail even if scientific literature suggests longer latency.

3. Clinical worsening restrictions. Section 10(2) limits clinical worsening factors to cases where the schizophrenia was suffered or contracted before or during service but did not arise out of service. That means if the schizophrenia arose out of service (i.e., was caused by it), the worsening factors do not apply , the claim should be based on onset factors instead. This subtlety is often missed, leading to incorrect claims.

4. Category 1B stressor exclusions. Witnessing human remains excludes closed body bags and open-casket viewings. This is a narrow definition. A veteran who viewed body bags from a helicopter would not satisfy the factor if the bags were closed. Similarly, witnessing a person being killed on television does not count because of the “witness” definition requiring direct experience.

5. Clinically significant disorder of mental health. Defined as a disorder “of sufficient severity to warrant ongoing management”. The note says this does not require that actual management was received. This is circular: the severity threshold is judged by whether management would be warranted, not whether it was given. This invites subjective assessment and potential inconsistency across decision-makers.

6. Inability to obtain appropriate clinical management. This factor (item 20) is vague. “Inability” could arise from lack of services, transport barriers, financial constraints, or refusal. The standard of “appropriate” management is not defined. It could lead to claims based on generic complaints about waiting times rather than genuine unavailability.

7. Cannabis use disorder vs. regular use. Factor 13 requires “cannabis use disorder” within 20 years before onset/worsening. This is a DSM-5 diagnosis requiring a pattern of use leading to clinically significant impairment. Factor 14 provides an alternative for those under 18 who used cannabis at least twice a week for six continuous months, also within 20 years. A claimant who used cannabis heavily but does not meet the diagnostic criteria for the disorder cannot rely on factor 13, and if over 18 cannot use factor 14. The distinction is easy to miss.

8. Specified List 1 vs. List 2. List 1 (for substance use disorder factor) includes amphetamines, cocaine, and opioids , but not cannabis, hallucinogens, or inhalants. Substance use disorder involving those latter drugs is not a factor unless it meets the separate cannabis use disorder factor (13) or the general factor 15 (which is for clinical worsening, not onset). For onset of schizophrenia, only alcohol use disorder or substance use disorder involving List 1 drugs is a factor (item 15). This gap means use of LSD or inhalants alone cannot be used for onset claims.

9. Childhood harm factor. Factor 1 requires serious physical, emotional, or sexual harm before age 18. But “serious” is not defined. The factor applies to “clinical onset” only , not worsening. So a veteran whose schizophrenia worsened due to childhood memories cannot use this factor unless it also contributed to first onset.

10. Death of a parent. Factor 11 requires the person was under 18 at the time of the parent’s death. The death must be within 10 years before clinical onset or worsening. If the parent died when the veteran was 20, even if devastating, no factor exists.

For a claimant veteran or member: first ensure the diagnosis meets DSM-5-TR criteria. Obtain a comprehensive psychiatric report that explicitly addresses the six criteria, including duration of symptoms, functional decline, and exclusion of mood disorders. The report should state clearly that the condition is schizophrenia, not schizoaffective disorder or substance-induced psychosis.

Identify which factor(s) may apply. For each potential factor, gather evidence of the event or condition, and the timing relative to clinical onset or worsening. For childhood harm, collect records from state child protection, hospital admissions, or credible witness statements. For infections (viral meningitis, Chlamydia pneumoniae, Toxoplasma gondii, SARS-CoV-2), obtain laboratory or hospital records confirming the infection. For traumatic brain injury, obtain medical records confirming the injury severity (e.g., Glasgow Coma Scale scores) and date. For stressors, record the exact nature of the event with witness statements if possible, and ensure it fits the category 1A or 1B definition. For drug use, obtain urine toxicology or prescription records.

For the stressor factors, note the “witness” definition excludes media exposure. If the stressor involved viewing human remains, ensure it was not a closed body bag or open-casket. If the stressor involved witnessing a killing, confirm the person saw it directly.

For cannabis use disorder, a formal DSM-5 diagnosis by a qualified clinician is required, not just self-reported use. Factor 14 (regular use under 18) does not require the disorder diagnosis but does require at least twice-weekly use for six months before age 18, and evidence of the use pattern (e.g., school counsellor reports, juvenile justice records).

For death of a related child or parent, obtain death certificates and evidence of the relationship (birth certificates, adoption orders). Ensure the timing windows are met.

For medication-induced worsening, document the specific medication (especially from Specified List 2), the dates of administration, and the temporal relationship to worsening. For cessation of antipsychotic therapy, document the drug and the date of cessation.

For inability to obtain appropriate clinical management, gather evidence of attempts to seek care (e.g., correspondence with health services, waitlist letters, evidence of remote location). This factor is likely the most difficult to prove and the most open to dispute.

The claimant should prepare a chronological statement linking the factor(s) to the onset or worsening of schizophrenia. A lawyer experienced in veterans’ law can assist in constructing a reasonable hypothesis argument.

For decision-makers: systematically verify each element. Is the diagnosis per DSM-5-TR? If the claimant has a diagnosis of schizoaffective disorder from a treating psychiatrist, reject unless the report can be corrected. Use the dictionary definitions strictly. For the “clinically significant disorder of mental health” factor, consider whether the cited disorder (e.g., alcohol use disorder) was indeed of sufficient severity to warrant ongoing management , but give the claimant the benefit of any doubt if a reasonable clinician could say so. For inability to obtain management, request evidence of actual attempts.

Maintain consistency by using a checklist based on section 9 factors. Cross-reference any factor linking to another disease (section 11) with the relevant SoP. Document all reasoning to withstand appeal. The AAT will review the decision de novo, so any error in applying the SoP definitions can be fatal.

The overall compliance burden is moderate for straightforward cases (e.g., a clear diagnosis with a documented combat stressor) but high for cases relying on historical childhood harm, infections, or substance use without contemporaneous records. The instrument’s structure encourages claimants to collect robust medical and personal histories as early as possible.